Implied Authority

In insurance, implied authority refers to an agent's authority to act beyond their express or written authority, as long as such actions are reasonably necessary to carry out their duties and responsibilities. This authority is assumed to exist based on the agent's position, past actions, or the customs of the industry.

For example, an insurance agent who has been authorized to sell auto insurance may have implied authority to make minor changes to a customer's policy, such as updating their contact information or adding a new driver to their policy. Implied authority may also be assumed when the agent has acted in a certain way in the past and the principal (the insurance company) has not objected to those actions.

Key features of implied authority include:

• It is not explicitly granted or stated in writing, but is assumed to exist.

• It arises from the agent's position and past actions.

• The agent must act within the scope of their duties and responsibilities.

• The insurance company is responsible for the actions of their agent, even if the agent exceeded their express authority.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.